Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

By Cramer Joyce A.   Amonkar Mayur M.   Hebborn Ansgar   Altman Roy  

Current Medical Research and Opinion, Vol. 21, Iss. 9, 2005-09 ,pp. : 1453-1460

Informa Healthcare

Access to resources Recommend Favorite

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

By Earnshaw S. R.   Graham C. N.   Ettinger B.   Amonkar M. M.   Lynch N. O.   Middelhoven H.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2517-2529

Informa Healthcare

Access to resources Recommend Favorite

Compliance with drug therapy for postmenopausal osteoporosis

By Weycker D.   Macarios D.   Edelsberg J.   Oster G.  

Osteoporosis International, Vol. 17, Iss. 11, 2006-11 ,pp. : 1645-1652

Springer Publishing Company

Access to resources Recommend Favorite

The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases

By Brankin Eamonn   Walker Mel   Lynch Niall   Aspray Terence   Lis Yvonne   Cowell Warren  

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1249-1256

Informa Healthcare

Access to resources Recommend Favorite